SCHEMBL3359832

SCHEMBL3359832

COc1ccc2c(CNc3ccsc3C(=O)Nc3ccc(OC(F)(F)F)cc3)ccnc2c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.79
MAP3K20 Q9NYL2 2/20 0.79
KIT P10721 2/20 0.79
RAF1 P04049 1/20 0.79
LCK P06239 1/20 0.79
RET P07949 1/20 0.79
CYP3A4 P08684 1/20 0.79
RIPK3 Q9Y572 1/20 0.79
FLT1 P17948 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
DGAT2 Q96PD7 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
MAPK7 Q13164 1/20 0.42
NTRK1 P04629 1/20 0.42
CLK2 P49760 1/20 0.42
IRAK1 P51617 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3364485 0.94 KDR (0.81) KDRMAP3K20KITRAF1LCK
SCHEMBL3361221 0.93 KDR (0.75) KDRMAP3K20KITRAF1LCK
SCHEMBL3362095 0.93 KDR (0.77) KDRMAP3K20KITRAF1LCK
SCHEMBL3359202 0.93 KDR (0.77) KDRMAP3K20KITRAF1LCK
SCHEMBL20805543 0.92 KDR (0.78) KDRMAP3K20KITRAF1LCK
SCHEMBL3362720 0.91 KDR (0.79) KDRMAP3K20KITRAF1LCK
SCHEMBL13846236 0.91 KDR (0.76) KDRMAP3K20KITRAF1LCK
Osi-930 SCHEMBL29352171 0.89 KDR (1.00) KDRMAP3K20KITRAF1LCK
Osi-930 SCHEMBL633719 0.89 KDR (1.00) KDRMAP3K20KITRAF1LCK
SCHEMBL3360168 0.88 KDR (0.70) KDRMAP3K20KITRAF1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO claimed
US-20230014124-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-01-19 US disclosed
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10905768-B1 Heterocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-02-02 US disclosed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
WO-2009152340-A2 2,3-SUBSTITUTED THIOPHENES IN LUNG INFLAMMATION THERAPIES OSI PHARMACEUTICALS, INC. (US) 2009-12-17 WO disclosed
WO-2009073139-A2 COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT OSI PHARMACEUTICALS, INC. (US) 2009-06-11 WO disclosed
US-20090136517-A1 COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT OSI PHARMACEUTICALS, INC. 2009-05-28 US disclosed
US-20090136517-A1 COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT OSI PHARMACEUTICALS, INC. 2009-05-28 US disclosed
EP-1807419-B1 (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2009-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136517-A1 COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT KIT, EGFR, AURKC KDR 57/4885MAP3K20 25/4885KIT 1/4885
US-20230014124-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION CRBN, MDM2, STUB1 KDR 801/4885MAP3K20 1440/4885KIT 2818/4885
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A KDR 1573/4885MAP3K20 1793/4885KIT 4712/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A KDR 1573/4885MAP3K20 1793/4885KIT 4712/4885
US-10905768-B1 Heterocyclic degronimers for target protein degradation CRBN, MDM2, STUB1 KDR 801/4885MAP3K20 1440/4885KIT 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.